Our Research Division focuses on understanding and improving human health, with a particular emphasis on pharmaceutical chemistry, pharmacology and improving pharmacy practice.
We cover a broad range of research interests from diseases such as heart disease, cancer, epilepsy and dementia to developing new compounds to treat cancer. We also work with patients and pharmacists to improve dementia patients' experience of drugs.
We have strong links with industry, including pharmaceutical companies such as Pfizer and GW Pharmaceuticals, and an outward-looking network of scientific collaborations spanning the globe (USA, Japan, Italy, Germany, Brazil, and Kazakhstan).
Our academics also work closely with several large facilities, including the Diamond Light Source, the ISIS Neutron Source and the Central Laser Facility at the Rutherford Appleton Laboratory in Oxfordshire.
Professor Ben Whalley has conducted cutting-edge research showing that non-psychoactive chemicals in cannabis could lead to more effective treatments for people with hard-to-treat epilepsy. Partners GW Pharmaceuticals began human clinical trials of new drugs containing these chemicals in the United States this year.
The Division hosts an exciting variety of events and seminars throughout the year:
Robot with a biological brain
Groundbreaking work carried out by the Pharmacy Research Division is transforming the lives of those with epilepsy.
Development of anti-epileptic cannabinoids: research initiated by Professor Ben Whalley and Dr Gary Stephens has revealed that non-psychoactive components of cannabis can control epileptic seizures in animal models.
This finding has led to a funded collaboration with GW Pharmaceuticals (UK) and Otsuka Pharmaceuticals (Japan) and subsequent human clinical drug trials. The results from Phase 1 of the trials have shown major quality-of-life improvements for the patients concerned.
Dr Mark Dallas, Lecturer in Cellular and Molecular Neuroscience in School of Pharmacy who specialises in Alzheimer's, says new study highlights need to invest in research and develop more opportunities for 'game-changing' scientists.
- Arjmand, S., Vaziri, Z., Behzadi, M., Abbassian, H., Stephens, G. J. and Shabani, M. (2015) Caught in the eye of the storm: a qualitative study of views and experiences of planned drug holidays from methylphenidate in child and adolescent ADHD treatment. Child and Adolescent Mental Health. ISSN 1475-3588 (In Press)
- Aitken, L. S., Hammond, L. E., Sundaram, R., Shankland, K., Brown, G. D. and Cobb, A. J. A. (2015) Asymmetric cyclopropanation of conjugated cyanosulfones using a novel cupreine organocatalyst: rapid access to d3-amino acids. Chemical Communications, 51 (70). pp. 13558-13561. ISSN 1359-7345
- Arjmand, S., Vaziri, Z., Behzadi, M., Abbassian, H., Stephens, G. J. and Shabani, M. (2015) Cannabinoids and tremor induced by motor-related disorders: friend or foe? Neurotherapeutics, 12 (4). pp. 778-787. ISSN 1933-7213
Find out more about our current projects:
- CPT Ltd; Dr Al Edwards
- Clinical Trials with GW Pharmaceuticals; Professor Ben Whalley
- Amino acids and skin moisturisers; Professor Adrian Williams
For specific enquiries, please contact:
Dr Patrick Lewis
Research Division Lead
Telephone: +44 (0)118 378 4561
- School of Pharmacy
- The Centre for Inter-Professional Postgraduate Education and Training (CIPPET)
- Chemical Analysis Facility
- Creating the Pharmacists of the Future